Memantine (Namenda) for moderate to severe Alzheimer's disease

被引：0
|
作者：
Ables, AZ [1 ]
机构：
[1] Spartanburg Family Med Residency Program, Spartanburg, SC USA
来源：
AMERICAN FAMILY PHYSICIAN | 2004年 / 69卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R1 [预防医学、卫生学];
学科分类号：
1004 ; 120402 ;
摘要：
Synopsis: Memantine (Namenda) is an N-methyl-d-aspartate'(NMDA) receptor blocker indicated for the treatment of moderate to severe Alzheimer's disease (AD). The NMDA receptor is activated by glutamate, the primary excitatory neurotransmitter in the brain. Overstimulation by glutamate may result in neuronal damage and has been implicated in neurodegenerative disorders such as AD. Memantine is the first pharmacologic agent approved by the US. Food and Drug Administration for the treatment of moderate to severe AD.
引用
收藏
页码：1491 / 1492
页数：2
相关论文
共 50 条
  • [31] Positive effects of memantine treatment in patients with moderate to severe Alzheimer's disease
    Gauthier, S
    Wirth, Y
    Moebius, HJ
    INTERNATIONAL PSYCHOGERIATRICS, 2005, 17 : 206 - 206
  • [32] Memantine and individual activities of daily living in moderate to severe Alzheimer's disease
    Feldman, H
    Schmitt, E
    Pfeiffer, E
    Graham, SM
    Bell, JM
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2005, 15 : S570 - S570
  • [33] Cost-effectiveness of memantine in moderate and severe Alzheimer's disease in Norway
    Rive, B.
    Aarsland, D.
    Grishchenko, M.
    Cochran, J.
    Lamure, M.
    Toumi, M.
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2012, 27 (06) : 573 - 582
  • [34] Functional benefits of memantine treatment for patients with moderate to severe Alzheimer's disease
    Wirth, Y
    Doody, RS
    Schmitt, FA
    Möbius, HJ
    NEUROBIOLOGY OF AGING, 2004, 25 : S205 - S205
  • [35] Functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease
    Wirth, Y.
    Doody, R. S.
    Schmitt, F. A.
    Moebius, H. J.
    Stoeffler, A.
    EUROPEAN JOURNAL OF NEUROLOGY, 2004, 11 : 193 - 193
  • [36] Memantine and individual activities of daily living in moderate to severe Alzheimer's disease
    Feldman, H
    Schmitt, F
    Pfeiffer, E
    Graham, S
    Bell, J
    INTERNATIONAL PSYCHOGERIATRICS, 2005, 17 : 200 - 201
  • [37] Treatment effects of Memantine on language in moderate to severe Alzheimer's disease patients
    Ferris, Steven
    Ihl, Ralf
    Robert, Philippe
    Winblad, Bengt
    Gatz, Gudrun
    Tennigkeit, Frank
    Gauthier, Serge
    ALZHEIMERS & DEMENTIA, 2009, 5 (05) : 369 - 374
  • [38] Cognitive effects of memantine in moderate to severe Alzheimer's disease: A responder analysis
    Tocco, M.
    Resnick, E. M.
    Graham, S. M.
    Pejovic, V.
    EUROPEAN JOURNAL OF NEUROLOGY, 2007, 14 : 54 - 55
  • [39] Functional benefit of memantine treatment in patients with moderate to severe Alzheimer's disease
    Wirth, Y
    Doody, RS
    Schmitt, FA
    Moebius, HJ
    Stoeffler, A
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2004, 14 : S327 - S327
  • [40] Memantine treatment benefits the language function in patients with moderate to severe Alzheimer's disease
    Ferris, S.
    Ihl, R.
    Robert, P.
    Winblad, B.
    Gauthier, S.
    Tennigkeit, F.
    EUROPEAN JOURNAL OF NEUROLOGY, 2010, 17 : 357 - 357
12345